Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
OPC-415 by Otsuka Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval
OPC-415 is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...